• Jiji

  • SHARE

Shionogi & Co. has said it aims to complete the final-phase clinical trial for its oral COVID-19 drug in December and start supplying it by the end of March next year.

The drugmaker will establish by the end of March 2022 a production system that can make doses of the orally taken medicine for at least 1 million people.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)